featured
Toripalimab Plus Axitinib vs Sunitinib as First-Line Treatment for Advanced Renal Cell Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Annals of Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study
Ann. Oncol 2023 Oct 20;[EPub Ahead of Print], XQ Yan, MJ Ye, Q Zou, P Chen, ZS He, B Wu, DL He, CH He, XY Xue, ZG Ji, H Chen, S Zhang, YP Liu, XD Zhang, C Fu, DF Xu, MX Qiu, JJ Lv, J Huang, XB Ren, Y Cheng, WJ Qin, X Zhang, FJ Zhou, LL Ma, JM Guo, DG Ding, SZ Wei, Y He, HQ Guo, BK Shi, L Liu, F Liu, ZQ Hu, XM Jin, L Yang, SX Zhu, JH Liu, YH Huang, T Xu, B Liu, T Sun, ZJ Wang, HW Jiang, DX Yu, AP Zhou, J Jiang, GD Luan, CL Jin, J Xu, JX Hu, YR Huang, J Guo, W Zhai, XN ShengFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.